[
  {
    "ts": "2025-12-02T06:06:52+00:00",
    "headline": "Morgan Stanley Bullish on Eli Lilly and Company (LLY)",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best dividend stocks to buy according to hedge funds. On November 23, Morgan Stanley analyst Terence Flynn maintained a Buy call on Eli Lilly, along with a price target of $1,290. In a different corporate update, dated November 24, Eli Lilly reported that it will present […]",
    "url": "https://finance.yahoo.com/news/morgan-stanley-bullish-eli-lilly-060652835.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f0366cbf-0525-3273-921a-668a982e8d2e",
      "content": {
        "id": "f0366cbf-0525-3273-921a-668a982e8d2e",
        "contentType": "STORY",
        "title": "Morgan Stanley Bullish on Eli Lilly and Company (LLY)",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best dividend stocks to buy according to hedge funds. On November 23, Morgan Stanley analyst Terence Flynn maintained a Buy call on Eli Lilly, along with a price target of $1,290. In a different corporate update, dated November 24, Eli Lilly reported that it will present […]",
        "pubDate": "2025-12-02T06:06:52Z",
        "displayTime": "2025-12-02T06:06:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/67016191d6d2df48fd6f8c9ec632b347",
          "originalWidth": 1920,
          "originalHeight": 1186,
          "caption": "Morgan Stanley Bullish on Eli Lilly and Company (LLY)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vJ7lKbloSPByVfgD_gqgZg--~B/aD0xMTg2O3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/67016191d6d2df48fd6f8c9ec632b347.cf.webp",
              "width": 1920,
              "height": 1186,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/szs6fG45A8w_rlV8N_NBzA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/67016191d6d2df48fd6f8c9ec632b347.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/morgan-stanley-bullish-eli-lilly-060652835.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/morgan-stanley-bullish-eli-lilly-060652835.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T09:10:00+00:00",
    "headline": "Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034",
    "summary": "Key market opportunities for abemaciclib include growing demand for targeted therapies in oncology, advancements in combination therapies with immuno-oncology, and integration of personalized medicine. Emerging markets in Asia-Pacific, expanded cancer treatment access, and innovations in therapy delivery methods further bolster growth. Abemaciclib Market Abemaciclib Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The \"Abemaciclib Market Report 2025\" report has been added to ResearchAndMarkets.c",
    "url": "https://finance.yahoo.com/news/abemaciclib-research-report-2025-eli-091000083.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "5eef4f6a-2e93-3003-8163-d88f1ecb934a",
      "content": {
        "id": "5eef4f6a-2e93-3003-8163-d88f1ecb934a",
        "contentType": "STORY",
        "title": "Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034",
        "description": "",
        "summary": "Key market opportunities for abemaciclib include growing demand for targeted therapies in oncology, advancements in combination therapies with immuno-oncology, and integration of personalized medicine. Emerging markets in Asia-Pacific, expanded cancer treatment access, and innovations in therapy delivery methods further bolster growth. Abemaciclib Market Abemaciclib Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The \"Abemaciclib Market Report 2025\" report has been added to ResearchAndMarkets.c",
        "pubDate": "2025-12-02T09:10:00Z",
        "displayTime": "2025-12-02T09:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/ddda3a59e715735ec1b7407ff5a69bde",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Abemaciclib Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SDRIcd63m_N9hqFIRHH3zw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/ddda3a59e715735ec1b7407ff5a69bde.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CiKDL_6RVKlUCm40O2GT3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/ddda3a59e715735ec1b7407ff5a69bde.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abemaciclib-research-report-2025-eli-091000083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abemaciclib-research-report-2025-eli-091000083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T13:21:00+00:00",
    "headline": "Best-Performing ETFs of November",
    "summary": "November muted for markets, but ETFs like SPYM, BWET, WNTR, LITP and OZEM stand out.",
    "url": "https://finance.yahoo.com/news/best-performing-etfs-november-132100056.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6d1ec5cf-2298-3283-9c7d-369ff6f76609",
      "content": {
        "id": "6d1ec5cf-2298-3283-9c7d-369ff6f76609",
        "contentType": "STORY",
        "title": "Best-Performing ETFs of November",
        "description": "",
        "summary": "November muted for markets, but ETFs like SPYM, BWET, WNTR, LITP and OZEM stand out.",
        "pubDate": "2025-12-02T13:21:00Z",
        "displayTime": "2025-12-02T13:21:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/49b19d5f77c2e6fb2ac483c58199d712",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MSRJWsL.FtoslgXQOYcRCw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/49b19d5f77c2e6fb2ac483c58199d712.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JYRdp73DKH_vnywdUjFJHg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/49b19d5f77c2e6fb2ac483c58199d712.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/best-performing-etfs-november-132100056.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/best-performing-etfs-november-132100056.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "UNG"
            },
            {
              "symbol": "OZEM"
            },
            {
              "symbol": "SPYM"
            },
            {
              "symbol": "WNTR"
            },
            {
              "symbol": "LITP"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BWET"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T16:30:55+00:00",
    "headline": "Wall Street Bulls are Pounding the Table Over Amazon, Eli Lilly, and Apple",
    "summary": "After a rough pullback, the major indices are attempting to rebound higher. Helping, not only is Bitcoin starting to rebound, but so are down but not out tech stocks. Plus, markets are optimistic that the Federal Reserve will cut interest rates again next week. We also continue to see a significant number of upgrades from ... Wall Street Bulls are Pounding the Table Over Amazon, Eli Lilly, and Apple",
    "url": "https://247wallst.com/investing/2025/12/02/wall-street-bulls-are-pounding-the-table-over-amazon-eli-lilly-and-apple/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "418fa0f8-fd7f-3c0a-91f0-14695643f4ca",
      "content": {
        "id": "418fa0f8-fd7f-3c0a-91f0-14695643f4ca",
        "contentType": "STORY",
        "title": "Wall Street Bulls are Pounding the Table Over Amazon, Eli Lilly, and Apple",
        "description": "",
        "summary": "After a rough pullback, the major indices are attempting to rebound higher. Helping, not only is Bitcoin starting to rebound, but so are down but not out tech stocks. Plus, markets are optimistic that the Federal Reserve will cut interest rates again next week. We also continue to see a significant number of upgrades from ... Wall Street Bulls are Pounding the Table Over Amazon, Eli Lilly, and Apple",
        "pubDate": "2025-12-02T16:30:55Z",
        "displayTime": "2025-12-02T16:30:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/e5e418254714602c7e082c2dd785ee8e",
          "originalWidth": 1024,
          "originalHeight": 1024,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Eu.BzYNnBh6oOqZ1c19qyA--~B/aD0xMDI0O3c9MTAyNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/24_7_wall_st__718/e5e418254714602c7e082c2dd785ee8e.cf.webp",
              "width": 1024,
              "height": 1024,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M1ikFhCUn3WcdxzvVRKdbA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/e5e418254714602c7e082c2dd785ee8e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/12/02/wall-street-bulls-are-pounding-the-table-over-amazon-eli-lilly-and-apple/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wall-street-bulls-pounding-table-163055144.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "AAPL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T10:15:00+00:00",
    "headline": "Janux sinks on ‘overreaction’ to prostate cancer data; RFK Jr. replaces ACIP chair",
    "summary": "Janux’s “masked” T cell engager had a lower response rate than reported last year. Elsewhere, Lilly dropped Zepbound’s price and ACIP named a new chairman days before a key vaccine meeting.",
    "url": "https://www.biopharmadive.com/news/janux-sinks-prostate-cancer-data-rfk-jr-acip-chair/806727/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "57ac6a7b-4b13-36cb-944b-30b885d6211a",
      "content": {
        "id": "57ac6a7b-4b13-36cb-944b-30b885d6211a",
        "contentType": "STORY",
        "title": "Janux sinks on ‘overreaction’ to prostate cancer data; RFK Jr. replaces ACIP chair",
        "description": "",
        "summary": "Janux’s “masked” T cell engager had a lower response rate than reported last year. Elsewhere, Lilly dropped Zepbound’s price and ACIP named a new chairman days before a key vaccine meeting.",
        "pubDate": "2025-12-02T10:15:00Z",
        "displayTime": "2025-12-02T10:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/janux-sinks-prostate-cancer-data-rfk-jr-acip-chair/806727/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/janux-sinks-overreaction-prostate-cancer-101500574.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JANX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]